Glaukos Highlights New Clinical Data on iDose TR and Corneal Cross-Linking at 2025 AAO Annual Meeting

Reuters

2025/10/14

Glaukos Highlights New Clinical Data on iDose TR and Corneal Cross-Linking at 2025 AAO Annual Meeting

Glaukos Corporation has announced that its technologies will be featured in various scientific programming at the upcoming 2025 American Academy of Ophthalmology (AAO) annual meeting, scheduled for October 18-20, 2025, in Orlando, Florida. Key clinical studies to be highlighted include the Travoprost Intracameral Implant (iDose® TR), with data on its ability to significantly reduce the need for topical intraocular pressure-lowering medications for up to 36 months, and its use in conjunction with cataract surgery with outcomes reported at 12 months. Additionally, results from a Phase 3, multicenter, randomized, sham/placebo-controlled trial demonstrating the safety and efficacy of epithelium-on corneal cross-linking (CXL) will be presented. These study findings will be presented at the AAO meeting, and detailed abstract information is available on the AAO website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251014079380) on October 14, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2575291410"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575291410\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575291410?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-14 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575291410","market":"fut","top_or_hot":-1,"title":"Glaukos Highlights New Clinical Data on iDose TR and Corneal Cross-Linking at 2025 AAO Annual Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Glaukos Highlights New Clinical Data on iDose TR and Corneal Cross-Linking at 2025 AAO Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Glaukos Corporation has announced that its technologies will be featured in various scientific programming at the upcoming 2025 American Academy of Ophthalmology (AAO) annual meeting, scheduled for October 18-20, 2025, in Orlando, Florida. Key clinical studies to be highlighted include the Travoprost Intracameral Implant (iDose® TR), with data on its ability to significantly reduce the need for topical intraocular pressure-lowering medications for up to 36 months, and its use in conjunction with cataract surgery with outcomes reported at 12 months. Additionally, results from a Phase 3, multicenter, randomized, sham/placebo-controlled trial demonstrating the safety and efficacy of epithelium-on corneal cross-linking (CXL) will be presented. These study findings will be presented at the AAO meeting, and detailed abstract information is available on the AAO website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251014079380) on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaukos Highlights New Clinical Data on iDose TR and Corneal Cross-Linking at 2025 AAO Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaukos Highlights New Clinical Data on iDose TR and Corneal Cross-Linking at 2025 AAO Annual Meeting\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-14 19:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Glaukos Highlights New Clinical Data on iDose TR and Corneal Cross-Linking at 2025 AAO Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Glaukos Corporation has announced that its technologies will be featured in various scientific programming at the upcoming 2025 American Academy of Ophthalmology (AAO) annual meeting, scheduled for October 18-20, 2025, in Orlando, Florida. Key clinical studies to be highlighted include the Travoprost Intracameral Implant (iDose® TR), with data on its ability to significantly reduce the need for topical intraocular pressure-lowering medications for up to 36 months, and its use in conjunction with cataract surgery with outcomes reported at 12 months. Additionally, results from a Phase 3, multicenter, randomized, sham/placebo-controlled trial demonstrating the safety and efficacy of epithelium-on corneal cross-linking (CXL) will be presented. These study findings will be presented at the AAO meeting, and detailed abstract information is available on the AAO website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251014079380) on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0009354923.USD","symbol_name":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL7g94kd:1","article_id":"2575291410","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575291410","pubTimestamp":1760439649,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Glaukos Corporation has announced that its technologies will be featured in various scientific programming at the upcoming 2025 American Academy of Ophthalmology  annual meeting, scheduled for October 18-20, 2025, in Orlando, Florida. Key clinical studies to be highlighted include the Travoprost Intracameral Implant , with data on its ability to significantly reduce the need for topical intraocular pressure-lowering medications for up to 36 months, and its use in conjunction with cataract surgery with outcomes reported at 12 months. Additionally, results from a Phase 3, multicenter, randomized, sham/placebo-controlled trial demonstrating the safety and efficacy of epithelium-on corneal cross-linking  will be presented. These study findings will be presented at the AAO meeting, and detailed abstract information is available on the AAO website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","LU1878469433.USD":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC","GKOS":"Glaukos Corp","BK4548":"巴美列捷福持仓","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","BK4082":"医疗保健设备"},"translate_title":"Glaukos在2025年AAO年会上重点介绍iDose TR和角膜交联的新临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GKOS":0.9},"content_text":"Glaukos Highlights New Clinical Data on iDose TR and Corneal Cross-Linking at 2025 AAO Annual Meeting\n    \n\n        Glaukos Corporation has announced that its technologies will be featured in various scientific programming at the upcoming 2025 American Academy of Ophthalmology (AAO) annual meeting, scheduled for October 18-20, 2025, in Orlando, Florida. Key clinical studies to be highlighted include the Travoprost Intracameral Implant (iDose® TR), with data on its ability to significantly reduce the need for topical intraocular pressure-lowering medications for up to 36 months, and its use in conjunction with cataract surgery with outcomes reported at 12 months. Additionally, results from a Phase 3, multicenter, randomized, sham/placebo-controlled trial demonstrating the safety and efficacy of epithelium-on corneal cross-linking (CXL) will be presented. These study findings will be presented at the AAO meeting, and detailed abstract information is available on the AAO website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251014079380) on October 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}